<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00808444</url>
  </required_header>
  <id_info>
    <org_study_id>111654</org_study_id>
    <nct_id>NCT00808444</nct_id>
  </id_info>
  <brief_title>Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age</brief_title>
  <official_title>Non-inferiority of a Commercial Lot of the Pneumococcal Vaccine GSK1024850A Compared to a Clinical Lot.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of the present study is to demonstrate that the changes in the manufacturing
      process for the commercial lot of the pneumococcal conjugate vaccine GSK1024850A have no
      clinical impact and that the immune responses are non-inferior to the immune responses
      induced by the clinical lot. The study will be conducted in Singapore and Malaysia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentrations of Antibodies Against Vaccine Components of the Pneumococcal Vaccine</measure>
    <time_frame>One month after primary immunization (month 4)</time_frame>
    <description>Concentrations are given as Geometric Mean Concentrations (GMCs) in microgram per milliliter (μg/mL).
Vaccine pneumococcal serotypes assessed included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of Antibody Against Protein D (PD)</measure>
    <time_frame>One month after primary immunization (month 4)</time_frame>
    <description>Concentration was expressed as GMC in GSK's 22F enzyme-linked-immunosorbent assay (ELISA) units per milliliter (EL.U/mL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-pneumococcal Vaccine Serotype Antibody Concentrations Equal to or Above 0.20 µg/mL</measure>
    <time_frame>One month after primary immunization (month 4)</time_frame>
    <description>Vaccine pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-pneumococcal Cross-reactive Serotype Concentrations Equal to or Above 0.20 µg/mL</measure>
    <time_frame>One month after primary immunization (month 4)</time_frame>
    <description>Anti-pneumococcal cross-reactive serotypes were 6A and 19A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes</measure>
    <time_frame>One month after primary immunization (month 4)</time_frame>
    <description>Vaccine pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
Opsonophagocytic activity was defined as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cut-off of the assay was an opsonic titer equal to or greater than 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes</measure>
    <time_frame>One month after primary immunization (month 4)</time_frame>
    <description>Cross-reactive pneumococcal serotypes were 6A and 19A.
Opsonophagocytic activity was defined as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cut-off of the assay was an opsonic titer equal to or greater than 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opsonophagocytic Titers of Cross-reactive Pneumococcal Serotypes</measure>
    <time_frame>One month after primary immunization (month 4)</time_frame>
    <description>Opsonophagocytic titers were expressed as GMTs.
Cross-reactive pneumococcal serotypes included 6A and 19A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Poliovirus Types 1, 2 and 3 Titers</measure>
    <time_frame>One month after primary immunization (month 4)</time_frame>
    <description>Titers were given as Geometric Mean Titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of Antibodies Against Diphteria Toxoid (DT) and Tetanus Toxoid (TT)</measure>
    <time_frame>One month after primary immunization (month 4)</time_frame>
    <description>Concentrations were defined as GMCs in international units per milliter (IU/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Antibody Against Hepatitis B Surface Antigen (HBs)</measure>
    <time_frame>One month after primary immunization (month 4)</time_frame>
    <description>Concentration was given as GMC in milli international units per milliliter (mIU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Antibody Against Rotavirus Immunoglobulin A (IgA)</measure>
    <time_frame>3 months after primary immunization (month 4)</time_frame>
    <description>Concentration was expressed as GMC in units per milliliter (U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Serious Adverse Events</measure>
    <time_frame>Following vaccination and throughout the entire study period (Month 0 to Month 4)</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opsonophagocytic Titers of Vaccine Pneumococcal Serotypes</measure>
    <time_frame>One month after primary immunization (month 4)</time_frame>
    <description>Titers are presented as Geometric Mean Titers (GMTs).
Pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local and General Symptoms.</measure>
    <time_frame>Within 4 days (day 0-3) after vaccination</time_frame>
    <description>Solicited local symptoms were pain, redness and swelling.
Solicited general symptoms were drowsiness, fever, irritability, loss of appetite, diarrhoea and vomiting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of Antibodies Against Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA), Pertactin (PRN)</measure>
    <time_frame>One month after primary immunization (month 4)</time_frame>
    <description>Concentrations are expressed as GMCs in EL.U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Antibody Against Polyribosyl-ribitol Phosphate (PRP)</measure>
    <time_frame>One month after primary immunization (month 4)</time_frame>
    <description>Concentrain was expressed as GMC in µg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Unsolicited Adverse Events</measure>
    <time_frame>Within 31 days (day 0-30) after vaccination</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">466</enrollment>
  <condition>Infections, Streptococcal</condition>
  <arm_group>
    <arm_group_label>Synflorix Clinical Lot &amp; Infanrix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Synflorix Commercial Lot Infanrix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal conjugate vaccine GSK1024850A (different lots)</intervention_name>
    <description>Intramuscular injection, 3 doses</description>
    <arm_group_label>Synflorix Commercial Lot Infanrix Group</arm_group_label>
    <arm_group_label>Synflorix Clinical Lot &amp; Infanrix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix hexa</intervention_name>
    <description>Intramuscular injection, 3 doses in Malaysia and 2 doses in Singapore</description>
    <arm_group_label>Synflorix Commercial Lot Infanrix Group</arm_group_label>
    <arm_group_label>Synflorix Clinical Lot &amp; Infanrix Group</arm_group_label>
    <other_name>DTPa-combined vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix-IPV/Hib</intervention_name>
    <description>Intramuscular injection, only for Visit 2 in Singapore</description>
    <arm_group_label>Synflorix Commercial Lot Infanrix Group</arm_group_label>
    <arm_group_label>Synflorix Clinical Lot &amp; Infanrix Group</arm_group_label>
    <other_name>DTPa-combined vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rotarix</intervention_name>
    <description>Oral, 2 doses</description>
    <arm_group_label>Synflorix Commercial Lot Infanrix Group</arm_group_label>
    <arm_group_label>Synflorix Clinical Lot &amp; Infanrix Group</arm_group_label>
    <other_name>HRV vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects between, and including 6-12 weeks of age at the time of the
             first vaccination.

          -  Subjects for whom the investigator believes that their parent(s)/guardian(s) can and
             will comply with the requirements of the protocol.

          -  Written or oral, signed or thumb-printed informed consent obtained from the
             parent(s)/guardian(s) of the child/ward.

          -  Free of any known or suspected health problems (as established by medical history and
             clinical examination before entering into the study).

          -  Born after a gestation period of &gt;= 36 to &lt;= 42 weeks.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccines within 30 days preceding the first dose of the study vaccines, or
             planned use during the study period.

          -  Concurrently participating in another clinical study, at any time during the study
             period.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs since birth.

          -  A family history of congenital or hereditary immunodeficiency.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition based on
             medical history and physical examination.

          -  Administration of immunoglobulins and/or any blood products since birth or planned
             administration during the study period (with the exception of hepatitis B
             immunoglobulins at birth).

          -  Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis
             B, Haemophilus influenzae type b and/or Streptococcus pneumoniae (with the exception
             of vaccines where the first dose can be given within the first two weeks of life).

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             during the period starting 30 days before each dose of vaccine and ending 7 days after
             Dose 1 and Dose 2 and 30 days after Dose 3.

          -  History of, or intercurrent diphtheria, tetanus, pertussis, hepatitis B,
             poliomyelitis, H. influenzae type b and rotavirus disease.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccines.

          -  History of any neurological disorders or seizures.

          -  Major congenital defects or serious chronic illness.

          -  Acute disease at the time of enrolment.

          -  Gastroenteritis within 7 days preceding the study vaccine administration.

          -  Any clinically significant history of chronic gastrointestinal disease including any
             uncorrected congenital malformation of the gastrointestinal tract, intussusception or
             other medical condition determined to be serious by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seremban, Negeri Sembilan</city>
        <zip>70300</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>149547</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>229899</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2008</study_first_submitted>
  <study_first_submitted_qc>December 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2008</study_first_posted>
  <results_first_submitted>October 25, 2010</results_first_submitted>
  <results_first_submitted_qc>October 25, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 19, 2010</results_first_posted>
  <last_update_submitted>October 6, 2016</last_update_submitted>
  <last_update_submitted_qc>October 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumococcal vaccine</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Primary vaccination</keyword>
  <keyword>Safety</keyword>
  <keyword>Pneumococcal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Streptococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>111654</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111654</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111654</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111654</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111654</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111654</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111654</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Synflorix Clinical Lot &amp; Infanrix Group</title>
          <description>Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
        </group>
        <group group_id="P2">
          <title>Synflorix Commercial Lot &amp; Infanrix Group</title>
          <description>Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="233"/>
                <participants group_id="P2" count="233"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="232"/>
                <participants group_id="P2" count="232"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Synflorix Clinical Lot &amp; Infanrix Group</title>
          <description>Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
        </group>
        <group group_id="B2">
          <title>Synflorix Commercial Lot &amp; Infanrix Group</title>
          <description>Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="233"/>
            <count group_id="B2" value="233"/>
            <count group_id="B3" value="466"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.3" spread="1.35"/>
                    <measurement group_id="B2" value="7.2" spread="1.30"/>
                    <measurement group_id="B3" value="7.3" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Concentrations of Antibodies Against Vaccine Components of the Pneumococcal Vaccine</title>
        <description>Concentrations are given as Geometric Mean Concentrations (GMCs) in microgram per milliliter (μg/mL).
Vaccine pneumococcal serotypes assessed included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
        <time_frame>One month after primary immunization (month 4)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Clinical Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
          <group group_id="O2">
            <title>Synflorix Commercial Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Antibodies Against Vaccine Components of the Pneumococcal Vaccine</title>
          <description>Concentrations are given as Geometric Mean Concentrations (GMCs) in microgram per milliliter (μg/mL).
Vaccine pneumococcal serotypes assessed included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-1 (N=219; 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" lower_limit="2.46" upper_limit="2.91"/>
                    <measurement group_id="O2" value="2.46" lower_limit="2.25" upper_limit="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4 (N=219; 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.95" lower_limit="3.59" upper_limit="4.36"/>
                    <measurement group_id="O2" value="3.14" lower_limit="2.84" upper_limit="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5 (N=219; 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.34" lower_limit="3.95" upper_limit="4.76"/>
                    <measurement group_id="O2" value="3.59" lower_limit="3.29" upper_limit="3.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B (N=219; 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" lower_limit="1.16" upper_limit="1.48"/>
                    <measurement group_id="O2" value="1.23" lower_limit="1.07" upper_limit="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7 (N= 218; 217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.10" lower_limit="2.83" upper_limit="3.39"/>
                    <measurement group_id="O2" value="3.20" lower_limit="2.92" upper_limit="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V (N=219; 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.34" lower_limit="3.03" upper_limit="3.69"/>
                    <measurement group_id="O2" value="3.14" lower_limit="2.83" upper_limit="3.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14 (N=219; 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.13" lower_limit="4.54" upper_limit="5.79"/>
                    <measurement group_id="O2" value="4.74" lower_limit="4.23" upper_limit="5.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C (N=219; 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="4.40" upper_limit="5.69"/>
                    <measurement group_id="O2" value="5.15" lower_limit="4.43" upper_limit="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F (N=219; 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.69" lower_limit="6.04" upper_limit="7.41"/>
                    <measurement group_id="O2" value="6.96" lower_limit="6.26" upper_limit="7.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F (N=219; 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" lower_limit="1.76" upper_limit="2.23"/>
                    <measurement group_id="O2" value="1.68" lower_limit="1.49" upper_limit="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentration of Antibody Against Protein D (PD)</title>
        <description>Concentration was expressed as GMC in GSK’s 22F enzyme-linked-immunosorbent assay (ELISA) units per milliliter (EL.U/mL).</description>
        <time_frame>One month after primary immunization (month 4)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Clinical Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
          <group group_id="O2">
            <title>Synflorix Commercial Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Antibody Against Protein D (PD)</title>
          <description>Concentration was expressed as GMC in GSK’s 22F enzyme-linked-immunosorbent assay (ELISA) units per milliliter (EL.U/mL).</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2543.6" lower_limit="2319.4" upper_limit="2789.4"/>
                    <measurement group_id="O2" value="1869.8" lower_limit="1671.2" upper_limit="2091.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-pneumococcal Vaccine Serotype Antibody Concentrations Equal to or Above 0.20 µg/mL</title>
        <description>Vaccine pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
        <time_frame>One month after primary immunization (month 4)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Clinical Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
          <group group_id="O2">
            <title>Synflorix Commercial Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-pneumococcal Vaccine Serotype Antibody Concentrations Equal to or Above 0.20 µg/mL</title>
          <description>Vaccine pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-1 (N= 219; 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4 (N= 219; 218</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5 (N=219; 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                    <measurement group_id="O2" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B (N=219; 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211"/>
                    <measurement group_id="O2" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F (N=218; 217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                    <measurement group_id="O2" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V (N=219; 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14 (N=219; 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                    <measurement group_id="O2" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C (N=219; 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F (N=219; 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                    <measurement group_id="O2" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F (N=219; 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215"/>
                    <measurement group_id="O2" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-pneumococcal Cross-reactive Serotype Concentrations Equal to or Above 0.20 µg/mL</title>
        <description>Anti-pneumococcal cross-reactive serotypes were 6A and 19A.</description>
        <time_frame>One month after primary immunization (month 4)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Clinical Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
          <group group_id="O2">
            <title>Synflorix Commercial Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-pneumococcal Cross-reactive Serotype Concentrations Equal to or Above 0.20 µg/mL</title>
          <description>Anti-pneumococcal cross-reactive serotypes were 6A and 19A.</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes</title>
        <description>Vaccine pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
Opsonophagocytic activity was defined as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cut-off of the assay was an opsonic titer equal to or greater than 8.</description>
        <time_frame>One month after primary immunization (month 4)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Clinical Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
          <group group_id="O2">
            <title>Synflorix Commercial Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes</title>
          <description>Vaccine pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
Opsonophagocytic activity was defined as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cut-off of the assay was an opsonic titer equal to or greater than 8.</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Opsono-1 (N=209; 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185"/>
                    <measurement group_id="O2" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-4 (N=207; 207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                    <measurement group_id="O2" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-5 (N=207; 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                    <measurement group_id="O2" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-6B (N=205; 206)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-7F (N=206; 208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-9V (N=207; 208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                    <measurement group_id="O2" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-14 (N=209; 208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-18C (N=204; 206)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202"/>
                    <measurement group_id="O2" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-19F (N=206; 206)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202"/>
                    <measurement group_id="O2" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-23F (N=209; 207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                    <measurement group_id="O2" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes</title>
        <description>Cross-reactive pneumococcal serotypes were 6A and 19A.
Opsonophagocytic activity was defined as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cut-off of the assay was an opsonic titer equal to or greater than 8.</description>
        <time_frame>One month after primary immunization (month 4)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Clinical Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
          <group group_id="O2">
            <title>Synflorix Commercial Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes</title>
          <description>Cross-reactive pneumococcal serotypes were 6A and 19A.
Opsonophagocytic activity was defined as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cut-off of the assay was an opsonic titer equal to or greater than 8.</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Opsono-6A (N=197; 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173"/>
                    <measurement group_id="O2" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-19A (N=197; 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opsonophagocytic Titers of Cross-reactive Pneumococcal Serotypes</title>
        <description>Opsonophagocytic titers were expressed as GMTs.
Cross-reactive pneumococcal serotypes included 6A and 19A.</description>
        <time_frame>One month after primary immunization (month 4)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Clinical Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
          <group group_id="O2">
            <title>Synflorix Commercial Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Opsonophagocytic Titers of Cross-reactive Pneumococcal Serotypes</title>
          <description>Opsonophagocytic titers were expressed as GMTs.
Cross-reactive pneumococcal serotypes included 6A and 19A.</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Opsono-6A (N=197;200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230.8" lower_limit="180.3" upper_limit="295.4"/>
                    <measurement group_id="O2" value="173.7" lower_limit="133.9" upper_limit="225.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-19A (N=197;199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" lower_limit="13.7" upper_limit="23.8"/>
                    <measurement group_id="O2" value="15.1" lower_limit="11.5" upper_limit="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Poliovirus Types 1, 2 and 3 Titers</title>
        <description>Titers were given as Geometric Mean Titers (GMTs).</description>
        <time_frame>One month after primary immunization (month 4)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Clinical Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
          <group group_id="O2">
            <title>Synflorix Commercial Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Poliovirus Types 1, 2 and 3 Titers</title>
          <description>Titers were given as Geometric Mean Titers (GMTs).</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Polio 1 (N=99; 93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="313.8" lower_limit="250.4" upper_limit="393.3"/>
                    <measurement group_id="O2" value="328.7" lower_limit="253.1" upper_limit="427.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2 (N=98; 93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278.7" lower_limit="225.4" upper_limit="344.7"/>
                    <measurement group_id="O2" value="229.1" lower_limit="176.9" upper_limit="296.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3 (N=97; 93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="408.8" lower_limit="330.1" upper_limit="506.4"/>
                    <measurement group_id="O2" value="449.4" lower_limit="351.9" upper_limit="573.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of Antibodies Against Diphteria Toxoid (DT) and Tetanus Toxoid (TT)</title>
        <description>Concentrations were defined as GMCs in international units per milliter (IU/mL)</description>
        <time_frame>One month after primary immunization (month 4)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Clinical Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
          <group group_id="O2">
            <title>Synflorix Commercial Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Antibodies Against Diphteria Toxoid (DT) and Tetanus Toxoid (TT)</title>
          <description>Concentrations were defined as GMCs in international units per milliter (IU/mL)</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-DT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.317" lower_limit="2.895" upper_limit="3.800"/>
                    <measurement group_id="O2" value="3.353" lower_limit="2.991" upper_limit="3.759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.879" lower_limit="4.358" upper_limit="5.502"/>
                    <measurement group_id="O2" value="4.476" lower_limit="4.013" upper_limit="4.992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Antibody Against Hepatitis B Surface Antigen (HBs)</title>
        <description>Concentration was given as GMC in milli international units per milliliter (mIU/mL).</description>
        <time_frame>One month after primary immunization (month 4)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Clinical Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
          <group group_id="O2">
            <title>Synflorix Commercial Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Antibody Against Hepatitis B Surface Antigen (HBs)</title>
          <description>Concentration was given as GMC in milli international units per milliliter (mIU/mL).</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1521.2" lower_limit="1129.7" upper_limit="2048.4"/>
                    <measurement group_id="O2" value="2114.1" lower_limit="1658.5" upper_limit="2694.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Antibody Against Rotavirus Immunoglobulin A (IgA)</title>
        <description>Concentration was expressed as GMC in units per milliliter (U/mL).</description>
        <time_frame>3 months after primary immunization (month 4)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Clinical Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
          <group group_id="O2">
            <title>Synflorix Commercial Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Antibody Against Rotavirus Immunoglobulin A (IgA)</title>
          <description>Concentration was expressed as GMC in units per milliliter (U/mL).</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.1" lower_limit="103.0" upper_limit="193.4"/>
                    <measurement group_id="O2" value="114.8" lower_limit="85.0" upper_limit="155.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Serious Adverse Events</title>
        <description>SAEs assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>Following vaccination and throughout the entire study period (Month 0 to Month 4)</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Clinical Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
          <group group_id="O2">
            <title>Synflorix Commercial Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Serious Adverse Events</title>
          <description>SAEs assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opsonophagocytic Titers of Vaccine Pneumococcal Serotypes</title>
        <description>Titers are presented as Geometric Mean Titers (GMTs).
Pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
        <time_frame>One month after primary immunization (month 4)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Clinical Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
          <group group_id="O2">
            <title>Synflorix Commercial Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Opsonophagocytic Titers of Vaccine Pneumococcal Serotypes</title>
          <description>Titers are presented as Geometric Mean Titers (GMTs).
Pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Opsono-1 (N=209;210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.9" lower_limit="102.7" upper_limit="161.7"/>
                    <measurement group_id="O2" value="122.1" lower_limit="98.3" upper_limit="151.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-4 (N=207;207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="698.3" lower_limit="619.6" upper_limit="786.9"/>
                    <measurement group_id="O2" value="609.3" lower_limit="519.6" upper_limit="714.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-5 (N=207;210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.9" lower_limit="109.0" upper_limit="149.9"/>
                    <measurement group_id="O2" value="98.6" lower_limit="83.0" upper_limit="117.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-6B (N=205;206)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="870.7" lower_limit="710.2" upper_limit="1067.6"/>
                    <measurement group_id="O2" value="619.2" lower_limit="483.4" upper_limit="793.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-7F (N=206;208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3905.8" lower_limit="3420.2" upper_limit="4460.4"/>
                    <measurement group_id="O2" value="3585.7" lower_limit="3119.8" upper_limit="4121.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-9V (N=207;208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1800.0" lower_limit="1596.6" upper_limit="2029.3"/>
                    <measurement group_id="O2" value="1851.3" lower_limit="1612.3" upper_limit="2125.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-14 (N=209;208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1521.0" lower_limit="1313.3" upper_limit="1761.6"/>
                    <measurement group_id="O2" value="1485.8" lower_limit="1280.5" upper_limit="1724.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-18C (N=204;206)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="533.5" lower_limit="461.8" upper_limit="616.4"/>
                    <measurement group_id="O2" value="383.9" lower_limit="319.3" upper_limit="461.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-19F (N=206;206)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="689.6" lower_limit="581.1" upper_limit="818.2"/>
                    <measurement group_id="O2" value="573.5" lower_limit="477.2" upper_limit="689.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-23F (N=209;207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2716.7" lower_limit="2316.3" upper_limit="3186.3"/>
                    <measurement group_id="O2" value="2379.5" lower_limit="2043.4" upper_limit="2770.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local and General Symptoms.</title>
        <description>Solicited local symptoms were pain, redness and swelling.
Solicited general symptoms were drowsiness, fever, irritability, loss of appetite, diarrhoea and vomiting.</description>
        <time_frame>Within 4 days (day 0-3) after vaccination</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort, which inlcuded all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Clinical Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
          <group group_id="O2">
            <title>Synflorix Commercial Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local and General Symptoms.</title>
          <description>Solicited local symptoms were pain, redness and swelling.
Solicited general symptoms were drowsiness, fever, irritability, loss of appetite, diarrhoea and vomiting.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort, which inlcuded all vaccinated subjects.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                    <measurement group_id="O2" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193"/>
                    <measurement group_id="O2" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of Antibodies Against Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA), Pertactin (PRN)</title>
        <description>Concentrations are expressed as GMCs in EL.U/mL.</description>
        <time_frame>One month after primary immunization (month 4)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Clinical Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
          <group group_id="O2">
            <title>Synflorix Commercial Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Antibodies Against Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA), Pertactin (PRN)</title>
          <description>Concentrations are expressed as GMCs in EL.U/mL.</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>EL.U/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT (N=109; 107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5" lower_limit="41.1" upper_limit="52.6"/>
                    <measurement group_id="O2" value="45.4" lower_limit="39.8" upper_limit="51.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA (N=107; 107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179.2" lower_limit="157.5" upper_limit="203.9"/>
                    <measurement group_id="O2" value="186.2" lower_limit="165.5" upper_limit="209.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN (N=109; 107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.1" lower_limit="123.2" upper_limit="164.0"/>
                    <measurement group_id="O2" value="128.3" lower_limit="110.9" upper_limit="148.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Antibody Against Polyribosyl-ribitol Phosphate (PRP)</title>
        <description>Concentrain was expressed as GMC in µg/mL.</description>
        <time_frame>One month after primary immunization (month 4)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Clinical Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
          <group group_id="O2">
            <title>Synflorix Commercial Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Antibody Against Polyribosyl-ribitol Phosphate (PRP)</title>
          <description>Concentrain was expressed as GMC in µg/mL.</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.745" lower_limit="7.807" upper_limit="12.164"/>
                    <measurement group_id="O2" value="6.387" lower_limit="5.051" upper_limit="8.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Unsolicited Adverse Events</title>
        <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
        <time_frame>Within 31 days (day 0-30) after vaccination</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Clinical Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
          <group group_id="O2">
            <title>Synflorix Commercial Lot &amp; Infanrix Group</title>
            <description>Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Unsolicited Adverse Events</title>
          <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Frequent AEs were assessed during the 4-day (day 0-3) follow-up period after vaccination for solicited AEs and 31-day (day 0-30) follow-up period for unsolicited AEs. SAEs were assessed from month 0 until study end (month 4).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Synflorix Clinical Lot &amp; Infanrix Group</title>
          <description>Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
        </group>
        <group group_id="E2">
          <title>Synflorix Commercial Lot &amp; Infanrix Group</title>
          <description>Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Spinal muscular atrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vith nerve parlysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Kawasaki's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="193" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="157" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="142" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="124" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="193" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="171" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

